Premium
Neurite outgrowth can be modulated in vitro using a tetracycline‐repressible gene therapy vector expressing human nerve growth factor
Author(s) -
Blesch Armin,
Uy Hua S.,
Diergardt Nicole,
Tuszynski Mark H.
Publication year - 2000
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/(sici)1097-4547(20000201)59:3<402::aid-jnr14>3.0.co;2-q
Subject(s) - nerve growth factor , neurite , genetic enhancement , neurotrophin , neurotrophic factors , biology , green fluorescent protein , in vivo , doxycycline , microbiology and biotechnology , viral vector , ex vivo , transfection , central nervous system , neuroscience , gene delivery , in vitro , gene , recombinant dna , genetics , receptor , antibiotics
The delivery of neurotrophic factors to the adult nervous system has potential applications for the treatment of neurodegenerative diseases and trauma. In vivo and ex vivo gene therapy offer a means of delivering growth factors and other therapeutic substances to the central nervous system (CNS) in an intraparenchymal, accurately targeted, and regionally restricted manner. Ideally, gene therapy delivery systems should also be regulatable, allowing exogenous control of amount of gene product delivery. In the present experiment, a tetracycline‐regulatable gene expression system was generated to determine whether controllable release of nerve growth factor (NGF) and green fluorescent protein (GFP) from primary rat fibroblasts could modulate biological responses (neurite outgrowth) in vitro. Using a tetracycline‐repressible construct, it was found that NGF mRNA, NGF protein, and NGF‐induced neurite outgrowth could be tightly regulated within a 24 hour period, and in a dose‐dependent fashion, by exposure to the tetracycline analog doxycycline. Similarly, levels of green fluorescence could be regulated in GFP‐transfected cells. These findings in a neurobiological system lay the framework for future studies using regulated neurotrophin delivery in in vivo models of neurodegenerative diseases and CNS injury. J. Neurosci. Res. 59:402–409, 2000 © 2000 Wiley‐Liss, Inc.